home / stock / drna / drna news

DRNA News and Press, Dicerna Pharmaceuticals Inc. From 03/24/21

Stock Information
Company Name: Dicerna Pharmaceuticals Inc.
Stock Symbol: DRNA
Market: NASDAQ
Website: dicerna.com
Menu
DRNA DRNA Quote DRNA Short DRNA News DRNA Articles DRNA Message Board
Get DRNA Alerts

News, Short Squeeze, Breakout and More Instantly...
DRNA - Dicerna to Present New GalXC-Plus(TM) Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Maire Osborn, Ph.D., Associate Director of Neuro Discovery at Dicerna...
DRNA - Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021

– Webinar To Feature Therapeutic Expert Henry Kranzler, M.D. – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, t...

DRNA - Dicerna and Roche start mid-stage Hepatitis B RG6346 trial

Dicerna Pharmaceuticals (DRNA) announces that its development partner Roche (RHHBY) has initiated RG6346 in a Roche-sponsored Phase 2 combination trial for the treatment of chronic hepatitis B virus ((HBV)) infection.RG6346 is an investigational GalXC RNAi therapeutic that Dicerna is dev...

DRNA - Dicerna Announces Roche's Initiation of GalXC(TM) RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection

– Phase 2 Initiation Triggers $25 Million Milestone to Dicerna – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics,...
DRNA - Dicerna Pharmaceuticals Inc (DRNA) Q4 2020 Earnings Call Transcript

Image source: The Motley Fool. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) Q4 2020 Earnings Call Feb 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Dicerna Pharmaceuticals Inc (DRNA) Q4 2020 Earnings Call Transc...

DRNA - Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q4 2020 Results - Earnings Call Transcript

Dicerna Pharmaceuticals, Inc. (DRNA) Q4 2020 Earnings Conference Call February 25, 2021 4:30 p.m. ET Company Participants Lauren Stival - Senior Director of IR Doug Fambrough - President and CEO Shreeram Aradhye - Chief Medical Officer Doug Pagan - CFO Jim Weissman - COO Rob Ciappenelli - Chi...

DRNA - Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update

– 2020 Highlights Include: Enrollment Completion of Pivotal PHYOX™2 Trial of Nedosiran for Primary Hyperoxaluria; Positive RG6346 Phase 1 Data for HBV; Positive Nedosiran Multidose Data from PHYOX3 Trial; First IND From Lilly Collaboration – – Compa...
DRNA - Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its financial results for the full year ende...

DRNA - Dicerna Is A Reasonably Priced Play In The Attractive RNAi Space

Dicerna has a huge pipeline of both internal and partnered RNAi products, one of which already has positive Phase 3 results. Dicerna has over $600 million in cash with more to come from its lucrative big pharma partnerships. Despite this, Dicerna trades at a huge valuation discoun...

DRNA - Dicerna Initiates PHYOX(TM)4 Trial of Nedosiran for Primary Hyperoxaluria Type 3

– PHYOX4 Data Expected Mid-Year 2021 – – Planned Nedosiran New Drug Application (NDA) Submission On Track for Third Quarter of 2021 – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”)...
Previous 10 Next 10